Sep 15

Human Papillomavirus (HPV) Prophylaxis– Expected to see a steady growth from 2015-2025

A total of approximately 7.3 Million people were vaccinated with HPV vaccines in 2016, as per the latest report of DelveInsight. Human Papillomavirus is a double stranded DNA virus that infects squamous epithelia including the skin and mucosae of the upper respiratory and anogenital tracts. HPV is a group of more than 200 related viruses, whose infections are so common that nearly all men and women will get at least one type of HPV at some point in their lives. The number of people getting vaccinated for these infections is estimated to increase in the coming years due to the expected increase in the coverage of HPV vaccines.

The HPV Prophylaxis market was estimated at 1.98 Billion in 2016 for 7MM’s. Due to proper awareness in the United States, it has a major hold over HPV Prophylaxis market and accounts for 90.5% of the total revenue coming from the 7 major markets (US, Germany, Spain, Italy, France, UK and Japan).

There were no approved vaccines for HPV prophylaxis till 2006, but after the approval of Gardasil (Quadrivalent vaccine) in U.S. and Cervarix (Bivalent vaccine) in Europe, the market scenario has improved. Also, the HPV market had a major setback when Japanese government withdrew its support for vaccines after a report published the side effects that girls had after vaccination. Japan has had a negligible contribution in the recent years to the total HPV market, in comparison to the other 6 major markets.

According to a study published in 2016, if Japan reinstates the governmental recommendation for the vaccine, this would induce a 4.1 % increase in the number of vaccination that the girls would undergo for HPV infections. It is expected that due to higher demand of Gardasil-9 (Merck) and increasing population pool, the market will increase in the coming years. Currently, there are only three approved HPV vaccines in the market and no emerging vaccines are in the pivotal stage of development. DelveInsight believes that there will be a steady growth in HPV prophylaxis market in the forecast period due to increase in vaccination rates and increasing awareness.

Insights by:
Harshit Saini
Associate Analyst





Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.